News | Hypertension | July 15, 2020

Omron and Mount Sinai Health Collaborate to Monitor High-risk Patient Blood Pressure at Home

Technology ensures close connection between patient and physician for remote hypertension monitoring, including COVID-19 patients

VitalSight is a HIPAA-compliant, Medicare-reimbursable home blood pressure monitoring solution that generally comes at no cost to the patient, depending on their coverage. The kit typically includes a digital blood pressure monitor with cuff, weight scale and digital medication tracker, as well as a data hub.

July 15, 2020 – Omron Healthcare Inc. and Mount Sinai Health System, New York City’s largest academic medical system, have teamed to offer patients the new VitalSight home blood pressure monitoring solution. Mount Sinai recently rolled out the VitalSight program to support the needs of their patients with hypertension.

The effort to provide VitalSight to patients is led by Rob Fields, M.D., SVP and chief medical officer for population health at Mount Sinai, and a team of clinical pharmacists, who are responsible for the day-to-day management of the program and coordination with physicians to ensure that patients receive individualized care.  

“The ability to monitor patients at home during the pandemic – and on an ongoing basis – is critical. Our collaboration with Omron Healthcare helps make patients active participants in their own healthcare and extends the reach of clinicians, who receive a continuous stream of their patients’ real-time health data so that they can proactively intervene as necessary,” Fields  said. “Additionally, we are focusing first on our most vulnerable patients, who bear the consequences of disparities in care – in part, due to lack of technology access. This program requires no technology and comes at no cost for the device, with little-to-no cost for service.”

“We’re excited to collaborate with such a prestigious healthcare institution as Mount Sinai, who played an instrumental role in shaping the value of VitalSight from early in its development. Now, they are leading the way for patients to use VitalSight from the privacy of their home, while staying closely connected to their physician,” explained Omron Healthcare President and CEO Ranndy Kellogg. 

VitalSight is the newest addition to the line of Omron Healthcare home blood pressure monitors, which are among the top doctor and pharmacist recommended systems.[1,2] The VitalSight kit complements Mount Sinai’s commitment to remotely monitor patients as part of its recent telehealth initiative, especially as providers care for COVID-19 patients who are recovering at home. 

VitalSight is a HIPAA-compliant, Medicare-reimbursable home blood pressure monitoring solution that generally comes at no cost to the patient, depending on their coverage. The kit typically includes a digital blood pressure monitor with cuff, weight scale and digital medication tracker, as well as a data hub. Exact devices may vary based on what the physician deems appropriate for each patient’s hypertension monitoring needs. VitalSight directly links to a physician’s electronic medical record (EMR), and is compatible with leading systems. Patients measure their blood pressure, weigh themselves and continue to take their medication as ordered by their physician. Securely encrypted data is automatically sent to the doctor’s EMR in real time, where it’s stored for reference unless a health concern is detected, in which case the physician’s office is alerted.

For more information: www.omronhealthcare.com

References:
1. Frost & Sullivan Survey, Blood pressure clinician perception tracker surveys. 17 July 2019.

2. U.S. News Staff 2019, U.S. News & World Report. https://health.usnews.com/health-products/top-rec-blood-pressure-monitors-14, accessed 8 August 2019.
 


Related Content

News | Hypertension

Sept. 04, 2025 — CorVista Health has published a new case series in the Journal of the American College of Cardiology ...

Home September 09, 2025
Home
News | Hypertension

Sept. 5, 2025 — Idorsia Ltd has announced a first-of-its-kind initiative with the Stanford Hypertension Center and Duke ...

Home September 08, 2025
Home
News | Hypertension

Aug. 19, 2025 — Idorsia Ltd recently announced its novel dual endothelin receptor antagonist (ERA), Tryvio (aprocitentan ...

Home August 27, 2025
Home
News | Hypertension

May 19, 2025 — Gradient Denervation Technologies recently announced the company’s pulmonary denervation system has ...

Home May 20, 2025
Home
News | Hypertension

April 9, 2025 — Idorsia Ltd recently announced that the US Food & Drug Administration (FDA), after having released ...

Home April 09, 2025
Home
News | Hypertension

Mar. 10, 2025-- Corcept Therapeutics Inc., a commercial-stage company engaged in the discovery and development of ...

Home March 11, 2025
Home
News | Hypertension

Jan. 9, 2025 — Gender-based racism through microaggressions may be linked to higher blood pressure postpartum and beyond ...

Home January 14, 2025
Home
News | Hypertension

Jan. 8, 2025 — Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing medicines ...

Home January 08, 2025
Home
News | Hypertension

Dec. 11, 2024 — Older adults whose blood pressure fluctuates over time may be more likely to have problems with thinking ...

Home December 19, 2024
Home
News | Hypertension

June 28, 2024 — AstraZeneca has set out a new ambition for Healthy Heart Africa, its flagship health equity initiative ...

Home June 28, 2024
Home
Subscribe Now